
price close busi octob
develop manufactur market devic
instrument orthoped
biomed devic servic
valuat rich reason buy pt
bottom line maintain buy rate follow result came
cg/street expect specif sale y/
organ slightli cg/street estim
strength driven momentum across entir portfolio particularli
orthoped vs estim continu trend posit given
new product launch earli launch mako china japan recent
entri intraop imag segment follow acquisit mobiu
imag septemb link
net-net continu view compel asset large-cap med-tech
believ core posit growth-ori investor given view
stable/improv market fundament robust new product cycl opportun
durabl oper leverag thesi deliv upsid guidanc remain
intact compani continu take market share across board benefit
meaning halo effect mako placement improv capit equip
market someth expect continue/acceler buy pt
revenu detail report sale growth organ
support us sale growth intern sale growth
xfx orthoped grew xfx strong perform knee
xfx hip xfx trauma/extrem xfx
medsurg also saw continu strong growth xfx driven strength
medic xfx support build-out
special sale forc endoscopi xfx though instrument
slightli softer expect xfx vs estim
neurotech spine slightli estim post xfx
growth manag note attribut short-term inventori constraint
spine slower expect ramp post integr
mako place mako system ww prior year includ
system place us mako procedur us exceed total knee
procedur exceed y/i compani provid specif
number hip procedur note sequenti build percentag mako
mention yet seen impact competit robot launch
previou year ask multipl time though look detail
competitor yet report note place mako low
dd percentag us ortho hospit demonstr earli natur opportun
potenti continu momentum beyond earli clinic data
begin trickl end year manag highlight
intern opportun next major driver mako growth
compani receiv approv japan subsequ sold robot open new
train facil hong kong open larg china market spine
side manag continu keep futur detail close vest note
alreadi see good technolog integr opportun cardan robot
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
maintain guidanc organ sale growth
state expect fall near high end rang full-year adjust ep
expect rang
previous adjust ep expect rang fx
impact expect headwind full year
bottom-lin perspect manag note fx expect neg impact
ep updat full year guidanc headwind
chang estim
made follow chang estim
figur chang estim
large-cap medic devic comp group trade mean price-to-earnings multipl
increas price target price target util
multipl appli pro forma ep estim
buy unchang target price octob
biomed devic servic
except ep newold newold newold revenu oper net stryker
figur matrix discount rate impli share price target
stryker
one world lead medic technolog compani
broadly-bas rang product orthoped signific presenc
medic specialti compani product includ implant use joint
replac trauma spinal surgeri surgic equip surgic
navig system endoscop commun system patient handl
emerg medic equip medic devic product use varieti
buy unchang target price octob
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl forma figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price octob
biomed devic servic
stryker corpor quarterli incom statementcanaccord genuiti kyle except per share good technolog special oper ex chg oper ex chg erest incom incom incom ex one-tim chg incom ex one-tim ep ex one-tim chg ep ex acq relat gross oper ex chg oper ex chg ex net charg net ex one-tim growth oper net incom charg ep charg ep ex acq growth net incom charg ep charg ep ex acq
buy unchang target price octob
biomed devic servic
stryker corpor revenu mixcanaccord genuiti kyle mix us y/i y/i xfx/x q/q q/q mixdomest stryker
